Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Only the general rosacea indication (inflammatory lesions of rosacea) and the existence of clinical trials evaluating once-daily at bedtime treatment with efficacy endpoints are supported by the provided label excerpts. Most other claims (route/prescriber details, papulopustular specificity, distributor/ANSM/patent/price, and multiple specific adverse effects) are unsupported by the supplied label sections.
Category Scores
Accurate Statements
Soolantra is for the treatment of rosacea in France.
Indications: “SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea.” (Location “in France” not addressed in excerpt.)
Soolantra has been approved by the French regulatory agency, ANSM, for the treatment of rosacea.
Indications content aligns with rosacea treatment: “SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea.” (ANSM approval authority not supported by excerpt.)
Soolantra’s efficacy and safety have been demonstrated in several clinical trials.
Clinical studies: “SOOLANTRA cream applied once daily at bedtime was evaluated… in two randomized, double-blind, vehicle controlled clinical trials…” (Explicit “safety demonstrated” wording is not shown in excerpt.)
Unsupported Statements
Soolantra is available by prescription from a dermatologist in France.
Prescription/dermatologist requirement and France-specific availability not supported by provided label excerpts.
Soolantra is for the treatment of papulopustular rosacea in France.
Provided indication specifies “inflammatory lesions of rosacea” and does not support papulopustular subtype or France-specific wording.
Galderma is the distributor of Soolantra in France.
Manufacturer/distributor information not present in provided label excerpts.
A clinical trial conducted in France showed significant improvement in patients with moderate to severe rosacea.
Label excerpt supports moderate/severe baseline distribution and superiority vs vehicle starting from 4 weeks, but does not support that the trial was conducted in France.
Soolantra can cause side effects including skin irritation.
Adverse reaction details are not provided in the supplied label excerpts (Section 6 has no text).
Soolantra can cause side effects including eye irritation.
Specific adverse effect claims are not supported by provided label excerpts (Section 6 has no text).
Soolantra can cause side effects including gastrointestinal problems.
Specific adverse effect claims are not supported by provided label excerpts (Section 6 has no text).
Soolantra is considered to be an expensive medication in France.
Economics/price not addressed in provided label excerpts.
Soolantra's patent is still in effect in France.
Patent status is not addressed in provided label excerpts.
Soolantra's patent will expire in an unspecified future date in France (according to DrugPatentWatch.com).
Patent/legal timing information is not addressed in provided label excerpts.
Soolantra’s efficacy and safety have been demonstrated in several clinical trials.
Clinical studies support efficacy evaluation; provided excerpt does not explicitly state “safety” demonstrated.
Soolantra has been approved by the French regulatory agency, ANSM, for the treatment of rosacea.
Label excerpt supports the indication wording but does not support ANSM approval or regulatory agency identification.
Contradictions
Low
AI Statement
Soolantra is available by prescription from a dermatologist in France.
Label Reference
No contraindication/warning/prescribing authority details provided in the supplied label excerpts to confirm or contradict this claim.
Important Omissions
Dosing instructions (beyond trial regimen) and administration details from the label are not evaluated because no dosage/administration section text was provided.
Importance:
Moderate
Contraindications, boxed warnings, precautions, drug interactions, and monitoring recommendations are not evaluated because the provided excerpts do not include those label sections (Section 6 and only partial sections were supplied).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported content in the provided excerpts pertains to the rosacea indication (inflammatory lesions of rosacea) and that SOOLANTRA was evaluated once daily at bedtime with superiority vs vehicle on efficacy endpoints. However, multiple specific adverse-effect claims are unsupported by the provided label excerpts, and most safety-relevant label sections were not provided, limiting verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Many claims are outside the provided label evidence (e.g., distributor/regulatory authority, country-specific trial conduct, patent/price) and several adverse-effect statements are unsupported because Section 6 text is not provided.
Suggested Improvement
Restrict statements to label-supported information from the provided excerpts (indication for inflammatory lesions of rosacea; trial description of once-daily at bedtime and efficacy endpoint results) and avoid unverified country-specific, regulatory, legal, economic, and adverse-event details unless corresponding label text is supplied.